Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1706311rdf:typepubmed:Citationlld:pubmed
pubmed-article:1706311lifeskim:mentionsumls-concept:C0020205lld:lifeskim
pubmed-article:1706311lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:1706311lifeskim:mentionsumls-concept:C0003316lld:lifeskim
pubmed-article:1706311lifeskim:mentionsumls-concept:C0003313lld:lifeskim
pubmed-article:1706311lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:1706311lifeskim:mentionsumls-concept:C0205169lld:lifeskim
pubmed-article:1706311lifeskim:mentionsumls-concept:C0237753lld:lifeskim
pubmed-article:1706311lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:1706311lifeskim:mentionsumls-concept:C0442805lld:lifeskim
pubmed-article:1706311lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:1706311lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:1706311lifeskim:mentionsumls-concept:C0872192lld:lifeskim
pubmed-article:1706311lifeskim:mentionsumls-concept:C0450442lld:lifeskim
pubmed-article:1706311pubmed:issue6lld:pubmed
pubmed-article:1706311pubmed:dateCreated1991-4-22lld:pubmed
pubmed-article:1706311pubmed:abstractTextThe use of immune complexes (IC) in an antibody excess, as immunizing agent, led to a large increase in the mouse polyclonal response to human SIgA. This enhanced response, as compared to SIgA alone, was analysed with mouse polyclonal anti-alpha chain antibodies (Ab). A kinetic study showed an early rise (between days 14 and 21) of the antibody response against the discontinuous epitopes of SIgA while the anti-IgA response increase was delayed. Induction of hybridomas with an IC consisting in SIgA containing an excess of anti-alpha chain Ab, increased 10-fold the number of positive wells. Moreover, two of these MAb were specific for weakly immunogenic epitopes. One recognized only SIgA (anti-C), i.e. the association between the alpha chain and the secretory component (SC), while the other mainly combined to IgA dimers (anti-P). Both these MAb will be useful tools for structural studies and for the dosage of secretory Ab.lld:pubmed
pubmed-article:1706311pubmed:languageenglld:pubmed
pubmed-article:1706311pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1706311pubmed:citationSubsetIMlld:pubmed
pubmed-article:1706311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1706311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1706311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1706311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1706311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1706311pubmed:statusMEDLINElld:pubmed
pubmed-article:1706311pubmed:monthDeclld:pubmed
pubmed-article:1706311pubmed:issn0272-457Xlld:pubmed
pubmed-article:1706311pubmed:authorpubmed-author:PillotJJlld:pubmed
pubmed-article:1706311pubmed:authorpubmed-author:IscakiSSlld:pubmed
pubmed-article:1706311pubmed:authorpubmed-author:BouigePPlld:pubmed
pubmed-article:1706311pubmed:issnTypePrintlld:pubmed
pubmed-article:1706311pubmed:volume9lld:pubmed
pubmed-article:1706311pubmed:ownerNLMlld:pubmed
pubmed-article:1706311pubmed:authorsCompleteYlld:pubmed
pubmed-article:1706311pubmed:pagination519-26lld:pubmed
pubmed-article:1706311pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1706311pubmed:meshHeadingpubmed-meshheading:1706311-...lld:pubmed
pubmed-article:1706311pubmed:meshHeadingpubmed-meshheading:1706311-...lld:pubmed
pubmed-article:1706311pubmed:meshHeadingpubmed-meshheading:1706311-...lld:pubmed
pubmed-article:1706311pubmed:meshHeadingpubmed-meshheading:1706311-...lld:pubmed
pubmed-article:1706311pubmed:meshHeadingpubmed-meshheading:1706311-...lld:pubmed
pubmed-article:1706311pubmed:meshHeadingpubmed-meshheading:1706311-...lld:pubmed
pubmed-article:1706311pubmed:meshHeadingpubmed-meshheading:1706311-...lld:pubmed
pubmed-article:1706311pubmed:meshHeadingpubmed-meshheading:1706311-...lld:pubmed
pubmed-article:1706311pubmed:meshHeadingpubmed-meshheading:1706311-...lld:pubmed
pubmed-article:1706311pubmed:meshHeadingpubmed-meshheading:1706311-...lld:pubmed
pubmed-article:1706311pubmed:meshHeadingpubmed-meshheading:1706311-...lld:pubmed
pubmed-article:1706311pubmed:meshHeadingpubmed-meshheading:1706311-...lld:pubmed
pubmed-article:1706311pubmed:year1990lld:pubmed
pubmed-article:1706311pubmed:articleTitleImmune complexes as immunizing agents to increase the number of monoclonal antibody producing hybrids and to deviate the response to poorly immunogenic epitopes.lld:pubmed
pubmed-article:1706311pubmed:affiliationInstitut Pasteur, Immunologie Microbienne, Paris, France.lld:pubmed
pubmed-article:1706311pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1706311pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1706311lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1706311lld:pubmed